I make a donation

ARMADA

Effects of Enoxaparine, Dalteparine and NFH on the activation markers of red blood cells in patients presenting an unstable angor or an acute coronary syndrome

Terminée

Remerciements de la Famille COLLET

Prix de Recherche Pr Jean-Philippe COLLET

La Grande Journée du Coeur (13 juin 2023)
Attention : plus que quelques places restantes !

La Grande Journée du Coeur (mardi 13 juin 2023)
Les présentations sont en ligne

Colloquium "Rythme et conduction" (23 avril 2024)
Inscrivez-vous !

objectif

Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction.

date de réalisation

2001

nombre de patients

141

nombre de centres participants

Monocentric

type de financement

Private (Sanofi-Aventis)

Publication

Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study)
Gilles Montalescot, Claire Bal-dit-Sollier, Daniela Chibedi, Jean-Philippe Collet, Thierry Soulat, Miles Dalby, Rémi Choussat, Ariel Cohen, Michel Slama, Phillipe-Gabriel Steg, Jean-Luc Dubois-Randé, Jean-Philippe Metzger, François Tarragano, Jean L Guermonprez, Ludovic Drouet, ARMADA Investigators
Publicated in The American Journal of Cardiology

Autres études

ACORES-2

En cours

Evaluate the effect of RAS blockers discontinuation versus continuation on clinical course of patients infected with COVID-19.

BIO-TAVI

En cours

Correlation between the platelet reactivity, the von Willebrand factor and bleeding and thrombotic events occuring during the year following TAVI

AMUNDSEN

En cours

A phase IV, multicentric, randomized, real-world pragmatic study that compares a strategy of early LDL reduction with anti-PCSK9 in patients defined as extreme high risk by 2019 ESC/EAS guidelines vs....